10月16日，巨子生物续跌逾15%，股价创年内新低！双十一电商大促提前启动，市场将重点关注可复美销售表现。
2025年双十一电商大促已经提前启动。华泰证券此前指出，在25Q2面临一定外部因素影响的背景下，巨子生物上半年收入与利润仍能双增，且盈利能力维持相对稳定，彰显品牌定力与业绩韧性。双11旺季临近，公司品牌宣传/达人推广等活动有望逐步恢复并带动公司H2增长提速。
值得注意的是，华熙生物9月底表示，已联合国家计量院等多家第三方检测机构对相关企业的相关产品展开检测，结果几十份检测结果均显示，相关产品中的重组胶原蛋白添加量未达标。华熙生物表示，“已将数十份检测报告提交国家药品监督管理局。”分析人士称，可复美在今年618电商大促中失意，市场将重点关注双11期间可复美电商销售表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
